Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy☆
References (21)
- et al.
Non-Hodgkin's lymphoma in a population with or at risk for acquired immunodeficiency syndrome: indications for intensive chemotherapy
Am J Med
(1989) - et al.
AIDS-associated non-Hodgkin lymphoma
Lancet
(1991) - et al.
Non-Hodgkin's lymphomas in 90 homosexual men
N Engl J Med
(1984) - et al.
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome
J Natl Cancer Inst
(1991) - et al.
AIDS-associated non-Hodgkin's lymphoma in San Francisco
JAMA
(1989) - et al.
Human immunodeficiency virus-related lymphoma
- et al.
Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma
- et al.
AIDS-related malignant lymphoma: results of prospective treatment trials
J Clin Oncol
(1987) - et al.
Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome
Arch Pathol Lab Med
(1991) - et al.
Interpretation of clinical trials in diffuse large-cell lymphoma
J Clin Oncol
(1988)
Cited by (135)
TRIM11 promotes lymphomas by activating the β-catenin signaling and Axin1 ubiquitination degradation
2020, Experimental Cell ResearchCitation Excerpt :According to tumor cells, lymphoma can be divided into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) [1], and according to different lymphocyte sources, lymphoma can also be divided into B cell, T cell and natural killer (NK) cell lymphoma Immunologic characterization of human malignant lymphomas [2–4]. At present, lymphoma is mainly treated by radiation, chemical drugs, bone marrow transplantation and surgery [5–8]. However, due to the high degree of heterogeneity of lymphoma, lymphomas of different pathological types and stages are highly different in terms of treatment intensity and prognosis.
The case of a diffuse large B-cell lymphoma (DLBCL) in a course of HIV
2010, HIV and AIDS ReviewIntensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: A prospective study
2007, BloodCitation Excerpt :Patients with good performance status (ECOG ≤ 2) had a good outcome as 70% were alive at 2 years. As expected in ARL,30,35,36 a CD4 cell count lower than 200 × 106/L was associated with poor outcome. Combining these 2 factors, we provide a prognosis index to define a patient subset with a clear benefit in survival when treated with LMB regimen.
AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART) - An African perspective
2007, Transfusion and Apheresis ScienceAIDS-related non-Hodgkin lymphoma: Final analysis of 485 patients treated with risk-adapted intensive chemotherapy
2006, BloodCitation Excerpt :Patients received CHOP-based chemotherapy after a pretreatment stratification of dose intensity according to their HIV score. This score was defined by the results of multivariate regression analysis in our previous trials.14,30 It is based on 3 independent risk factors (Eastern Cooperative Oncology Group [ECOG] performance status of 2 to 4, prior AIDS, and a CD4+ cell count below 0.10 × 109/L [100/mm3]) and leads to patient classification according to 3 degrees of risk: good (HIV score, 0 factors), intermediate (HIV score, 1 factor), and poor (HIV score, 2 to 3 factors).
- ☆
This work was supported by ANRS (Agence Nationale de Recherche sur le SIDA), Paris, France, ANLAIDS (Associazione Italiana Lotta contro l'AIDS), Roma, Italy, and GELA (Groupe d'Etude des Lymphomes de l'Adulte), Paris, France.